Keyphrases
Biliary Tract Cancer
34%
Biomarker Potential
13%
C-reactive Protein
16%
Carbohydrate Antigen 19-9 (CA19-9)
29%
Checkpoint Inhibitors
21%
Chemotherapy
18%
Circulating Proteins
33%
Combination Chemotherapy
10%
Confidence Interval
20%
Diagnostic Biomarker
15%
Fibroblast Activity
10%
Fibroblasts
11%
Gemcitabine
16%
Hazard Ratio
10%
Healthy Controls
11%
Immune Checkpoint Inhibitors
26%
Inflammatory Biomarkers
16%
Interleukin-6
23%
Ipilimumab
26%
Lung Cancer
15%
Metastatic Pancreatic Cancer
13%
Metastatic Pancreatic Ductal Adenocarcinoma
25%
Nivolumab
27%
Older Patients
11%
Overall Survival
54%
Pancreatic Cancer
89%
Pancreatic Ductal Adenocarcinoma
100%
Phase II Study
23%
PRO-C3
24%
PRO-C6
15%
Prognostic Biomarker
18%
Prognostic Value
19%
Propeptide
24%
Protein Biomarkers
13%
Protein Signature
14%
Radiotherapy
15%
Randomized Controlled Trial
14%
Randomized Phase II Trial
21%
Resectable Pancreatic Cancer
27%
Resection
16%
Serum Levels
10%
Solid Tumors
19%
Stereotactic Body Radiotherapy
21%
Tocilizumab
13%
Transforming Growth Factor-β
13%
Tumor Fibrosis
25%
Tumor Microenvironment
12%
Tumor Subtype
11%
Type III Collagen
18%
YKL-40
31%
Pharmacology, Toxicology and Pharmaceutical Science
Adenocarcinoma
6%
Adverse Event
7%
Arthritis
6%
Biliary Tract Cancer
14%
Biological Marker
67%
C Reactive Protein
14%
CA 19-9 Antigen
11%
Capecitabine
6%
Chemotherapy
21%
Chronic Disease
6%
Circulating Tumor DNA
7%
Clinical Study
6%
Cohort Study
6%
Colitis
13%
Collagen Type 3
17%
Collagen Type 5
6%
Comorbidity
6%
Diarrhea
8%
Disease
15%
Enzyme-Linked Immunosorbent Assay
6%
Fibrillar Collagen
10%
Fibrosis
26%
Gemcitabine
15%
Hyaluronic Acid
6%
Hypovitaminosis D
6%
Immune Checkpoint Inhibitor
30%
Interleukin 15
6%
Interleukin 6
14%
Ipilimumab
19%
Life Expectancy
6%
Long Term Survival
6%
Lung Cancer
7%
Malignant Neoplasm
24%
Monotherapy
6%
Mouse Model
6%
Neoplasm
32%
Nivolumab
19%
Overall Survival
49%
Paclitaxel
6%
Pancreas Adenocarcinoma
70%
Pancreas Cancer
97%
Pancreas Disease
8%
Placebo
6%
Progression Free Survival
6%
Solid Malignant Neoplasm
21%
Tocilizumab
13%
Tumor Growth
7%
Tumor Microenvironment
11%
Vitamin D
6%
Vitamin D Deficiency
6%
Medicine and Dentistry
Adenocarcinoma
13%
Adjuvant Therapy
9%
Advanced Cancer
10%
Adverse Event
7%
Age Difference
6%
Biliary Tract Cancer
27%
Biological Marker
42%
Cancer Therapy
14%
Capecitabine
6%
Circulating Tumor DNA
7%
Collagen Type 3
9%
Combination Chemotherapy
10%
Diagnosis
11%
Disease
16%
Exercise
7%
Extracellular Matrix
8%
Fibroblast
6%
Fibrosis
8%
Gemcitabine
16%
Hazard Ratio
10%
Immune Checkpoint Inhibitor
21%
Immunotherapy
7%
Interleukin 15
6%
Interleukin 6
11%
Interleukin-6
12%
Ipilimumab
24%
Liver Metastasis
7%
Long Term Survival
8%
Lung Cancer
8%
Malignant Neoplasm
24%
Metastatic Colorectal Cancer
6%
Neoplasm
16%
Nivolumab
25%
Oncology
8%
Overall Survival
38%
Pancreas Adenocarcinoma
60%
Pancreas Cancer
89%
Pancreas Disease
8%
Pancreatic Surgery
6%
Proportional Hazards Model
6%
Quality of Life
6%
Radiation Therapy
7%
Randomized Controlled Trial
14%
Retrospective Cohort Study
6%
Solid Malignant Neoplasm
7%
Stereotactic Body Radiation Therapy
23%
Surgery
12%
Symptom
13%
Symptomatic Treatment
6%
Tocilizumab
13%